Reata Pharmaceuticals (RETA) PT Cut to $315 but Stifel Recommends Buying the Weakness
Tweet Send to a Friend
Stifel analyst Adam Walsh lowered the price target on Reata Pharmaceuticals (NASDAQ: RETA) to $315.00 (from $362.00) but is recommending ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
